Xpeng G9L completes first production trial at Magna's Graz facility

XPeng Inc. (NYSE: XPEV) announced that its G9L SUV has completed its first production trial at Magna's vehicle manufacturing facility in Graz, Austria, making it the fourth Xpeng model to be produced in Europe alongside the G6, G9, and P7+.

The production milestone comes one year after Xpeng and Magna began local manufacturing at the Graz site in the third quarter of 2025. The two companies are expanding their cooperation to support Xpeng's growing vehicle portfolio for European and global markets.

Following the production trial, the first pre-production G9L will travel 1,324 kilometers from Graz to Paris ahead of its global premiere at the Paris Motor Show on October 12, where Xpeng plans to open orders for the vehicle. The journey is intended to demonstrate the vehicle's charging capability, safety systems, and driving performance.

Xpeng says the G9L has been developed for launch across 64 countries and regions, with a validation program covering 26 countries over three years and approximately 6.74 million kilometers of road testing. The vehicle has completed 192 crash tests and more than 110 testing protocols, including both left- and right-hand-drive configurations.

The G9L's standard chassis includes dual-chamber air suspension, intelligent variable damping, and rear-wheel steering with up to 15 degrees of steering angle.

Xpeng reported that its overseas deliveries surpassed 20,000 units in the second quarter of 2026, up 81% year-on-year, with overseas markets contributing 25% of first-half revenue at an average selling price exceeding €40,000. The company has delivered more than 60,000 vehicles in Europe to date.

Roland Prettner, President of Magna Complete Vehicles, said the G9L milestone "demonstrates how strong teamwork can translate Xpeng's product vision and technical requirements into robust production processes."

You May Also Be Interested In

• Alpha Tau signs MOU with Samsung Medical Center for pancreatic cancer trial
• Quantum X Labs reports error reduction gains on Nvidia and IBM hardware
• AstraZeneca launches sunvozertinib for EGFR exon 20 NSCLC